Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Jun;9(6):e414-e427.
doi: 10.1016/S2352-3018(22)00077-7.

Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression

Samira Hosseini-Hooshyar  1 , Behzad Hajarizadeh  2 , Sahar Bajis  2 , Matthew Law  2 , Naveed Z Janjua  3 , Daniel S Fierer  4 , David Chromy  5 , Jürgen K Rockstroh  6 , Thomas C S Martin  7 , Patrick Ingiliz  8 , Chien-Ching Hung  9 , Gregory J Dore  2 , Marianne Martinello  2 , Gail V Matthews  2
Affiliations
Meta-Analysis

Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression

Samira Hosseini-Hooshyar et al. Lancet HIV. 2022 Jun.

Abstract

Background: The benefits of direct-acting antivirals towards the elimination of hepatitis C virus (HCV) in people living with HIV are decreased when individuals are reinfected with HCV following treatment. We aimed to systematically review the existing evidence of HCV reinfection risk after treatment among people living with HIV, including people who inject drugs and men who have sex with men (MSM), and to identify the factors that explain heterogeneity in the incidence of HCV reinfection.

Methods: For this systematic review and meta-analysis, we searched PubMed, Scopus, Web of Science, Cochrane, PsycINFO, and conference presentations from date of database inception to Jan 10, 2022, for clinical trials and cohort studies providing data that could be used to calculate the incidence of HCV reinfection following HCV treatment. Random-effect meta-analysis models were used to calculate rate estimates. Study-level factors contributing to heterogeneity of reinfection estimates were assessed using meta-regression. This study is registered with PROSPERO, CRD42019146973.

Findings: 41 studies, predominantly conducted in Europe, were included, with a total of 9024 participants. The incidence of reinfection was 3·76 cases per 100 person-years of follow-up (95% CI 2·80-5·05; I2 85·9%) among people living with HIV overall, 6·01 (4·54-7·95; 74·1%) among MSM, and 3·29 (2·01-5·39; 83·9%) among people who inject drugs. A similar incidence of reinfection was observed following interferon-based therapy (4·92 cases per 100 person-years of follow-up, 3·30-7·32; I2 78·3%) and direct-acting antiviral therapy (3·88, 2·51-6·01; 85·4%). A higher proportion (≥85%) of MSM in the study population (adjusted rate ratio 2·66, 95% CI 1·37-5·15) and recent HCV infection (2·22, 1·09-4·55) were associated with an increased incidence of reinfection; a longer duration of follow-up after treatment (0·97, 0·96-0·99) was associated with a decreased incidence.

Interpretation: Risk of HCV reinfection following treatment in people living with HIV was highest among MSM and those with recent HCV infection. Continued scale-up of HCV treatment and ongoing HCV screening and treatment of infection in this patient population should reduce viraemic burden and risk of reinfection.

Funding: None.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests ML reports grants from Gilead Sciences, Janssen-Cilag, and ViiV Healthcare, outside the submitted work. DC reports personal fees from Merck; and non-financial support from Merck, Gilead, and GlaxoSmithKline–ViiV, outside the submitted work. JKR reports personal fees from Abivax, Galapagos, Gilead, Janssen, Merck, and ViiV, outside the submitted work. PI reports grants from Gilead and Abbott; and personal fees from Gilead, MYR Pharmaceuticals, AbbVie, and ViiV, outside the submitted work. C-CH reports grants and personal fees from Gilead Sciences and ViiV, outside the submitted work. GJD reports grants from Gilead Sciences, AbbVie, and Merck, outside the submitted work. GVM reports grants from Gilead and AbbVie, outside the submitted work. All other authors declare no competing interests.

Comment in

Publication types

Substances

LinkOut - more resources